Journal
MOLECULAR THERAPY
Volume 20, Issue 1, Pages 21-27Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/mt.2011.214
Keywords
-
Categories
Funding
- National Institutes of Health [1R01HD052682-01A1, HL59412, 5F32HL095282-02]
- NIDDK [P01 DK58327]
- Johns Hopkins University
Ask authors/readers for more resources
Pompe disease is a form of muscular dystrophy due to lysosomal storage of glycogen caused by deficiency of acid alpha-glucosidase (GM). Respiratory failure in Pompe disease has been attributed to respiratory muscle dysfunction. However, evaluation of spinal tissue from Pompe patients and animal models indicates glycogen accumulation and lower nnotoneuron pathology. We hypothesized that restoring GAA enzyme activity in the region of the phrenic motor nucleus could lead to improved breathing in a murine Pompe model (the Gaa(-/-) mouse). Adeno-associated virus serotype 5 (AAV5), encoding either GM or green fluorescent protein (GFP), was delivered at the C(3)-C(4) spinal level of adult Gaa(-/-) mice and the spinal cords were harvested 4 weeks later. AAV5-GAA injection restored spinal GM enzyme activity and GM immunostaining was evident throughout the cervical ventral horn. The periodic acid Schiff (PAS) method was used to examine neuronal glycogen accumulation, and spinal PAS staining was attenuated after AAV5-GAA injection. Lastly, plethysmography revealed that minute ventilation was greater in unanesthetized AAV5-GAA versus AAV5-GFP treated Gaa(-/-) mice at 1-4 months postinjection. These results support the hypothesis that spinal cord pathology substantially contributes to ventilatory dysfunction in Gaa(-/-) mice and therefore requires further detailed evaluation in patients with Pompe disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available